CL-82198 is a selective inhibitor of MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs. CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression.
体外研究
CL-82198 (10 μM; 24 hours) significantly reduces LS174 cell migration.
CL-82198 decreases CTGF and TGF-β1 protein levels in hepatic stellate cells.
体内研究
CL82198 (1-10 mg/kg; i.p.; every other day for 12 weeks) prevents and decelerates MLI-induced osteoarthritis progression.
Animal Model:
10-week-old C57BL/6J mice (performed MLI surgery)
Dosage:
1, 5, 10 mg/kg body weight
Administration:
Intraperitoneal injection; every other day for 12 weeks
Result:
Prevented and decelerated MLI-induced osteoarthritis progression.
分子式
C17H22N2O3
分子量
302.37
CAS号
307002-71-7
运输条件
Room temperature in continental US; may vary elsewhere.